Poewe WH, Wenning GK. The natural history of Parkinson’s disease. Neurology 1996; 47: S146-S152

2 Hoehn M. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983; 253–264.

3 Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neuroepidemiology 1996; 14: 317-335.

4 Marttila RJ, Rinne UK. Epidemiological approaches to the etiology of Parkinson’s disease. Acta Neurol Scand Suppl 1989; 126: 13-18.

5 Stacy M, Hauser R. Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson’s disease. J Neural Transm 2007; 114: 211-217.

6 Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord 2005; 20: 224-230.

7 Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 2005; 252: iv37-iv42.

8 Poewe W. Treatment in the early stages of Parkinson’s disease. Movement Disorders 1996; 11: 9 Abstract M28.

9 Hauser RA. Parkinson’s disease: Questions and Answers. 5th edition . Merit Publishing International; Boca Raton, FL. 2006.

10 Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X.

The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 2008; 14: 205-212.

11 Hauser RA, Russ H, Haeger DA, Bruguiere-Fontenille M, Muller T, Wenning GK. Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. Clin Neuropharmacol 2006; 29: 322-330.

Hyödyllistä tietoa Parkinsonin taudin kanssa  sopeutumiseen